Evidence map›Paper›PMID 28631038›Full record

ArticleMedical molecular morphology2017

The significance of TIMD4 expression in clear cell renal cell carcinoma.

Hiromu Yano, Takanobu Motoshima, Chaoya Ma, Cheng Pan, Sohsuke Yamada, Toshiyuki Nakayama, Shohei Kitada, Naohiro Fujimoto, Tomomi Kamba, Motohiro Takeya and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical molecular morphology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Hiromu YanoDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Chuouku, Kumamoto, 860-8556, Japan.
Takanobu MotoshimaDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Chuouku, Kumamoto, 860-8556, Japan.
Chaoya MaDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Chuouku, Kumamoto, 860-8556, Japan.
Cheng PanDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Chuouku, Kumamoto, 860-8556, Japan.
Sohsuke YamadaDepartment of Pathology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Toshiyuki NakayamaDepartment of Pathology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Shohei KitadaDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Naohiro FujimotoDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Tomomi KambaDepartment of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Motohiro TakeyaDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Chuouku, Kumamoto, 860-8556, Japan.
Yoshihiro KomoharaDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Chuouku, Kumamoto, 860-8556, Japan. ycomo@kumamoto-u.ac.jp.
Kumamoto University · JPUniversity of Occupational and Environmental Health Japan · JP

Funding

KAKENHI 16H05162KAKENHI 16K11013
6 · The paper itself

Abstract

T-cell immunoglobulin and mucin domain (TIMD) family genes are related to innate immune responses. TIMD4 is a receptor for phosphatidylserine and is involved in the phagocytosis of apoptotic cells by macrophages. In the present study, we found that TIMD4 is expressed on the cancer cells of patients with clear cell renal cell carcinoma (ccRCC). TIMD4 was immunostained in the resected samples of 89 patients diagnosed as ccRCC. High expression of TIMD4 in cancer cells was closely related to short progression free survival time; however, it was not correlated with other clinicopathological factors. Intracellular expression of TIMD4 was observed in the RCC cell line, 786-O. In vitro studies using 786-O cells and shRNA targeting TIMD4 indicated that TIMD4 expression was associated with resistance to sorafenib but not with cell proliferation. TIMD4 might be useful as a prognostic factor and may also be a new target for therapy of ccRCC.

Indexed as

AgedAntineoplastic AgentsCarcinoma, Renal CellCell Line, TumorCell ProliferationDisease-Free SurvivalDrug Resistance, NeoplasmFemaleGene ExpressionHumansKidney NeoplasmsMaleMembrane ProteinsMiddle AgedNiacinamidePhenylurea CompoundsAntineoplastic AgentsMembrane ProteinsNiacinamidePhenylurea CompoundsRNA, Small InterferingSorafenibTIMD4 protein, human786-OPrognostic factorRCCSorafenibTIMD4

Identifiers

PMID28631038
OpenAlexW2658552913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.